SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk ($SNDK) is trending due to its inclusion in the S&P 500, replacing Interpublic Group ($IPG), sparking bullish sentiment. The community is discussing whether the recent surge is justified, with some anticipating a pullback while others foresee continued upward momentum towards $300. Analysts' price target increases and reported undersupply in the NAND market are also fueling the conversation.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as investors digest the implications of its oral semaglutide failing to meet endpoints in Alzheimer's trials, leading to a significant stock drop. The community is debating whether this sell-off is an overreaction, considering the company's continued dominance in the weight loss market and the potential approval of its oral Wegovy. Some investors view the dip as a buying opportunity, while others express concern about the company's future prospects amidst increasing competition.

Carnival Corp. engages in the operation of cruise ships. It operates through the following business segments: North America and Australia (NAA) Cruise, Europe and Asia (EA) Cruise Operations, Cruise Support, and Tour and Others. The North America and Australia (NAA) Cruise segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe and Asia (EA) Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corp. - Ordinary Shares (Paired Stock)

Carnival Corp

Cruise line stocks, including CCL, experienced a sudden drop, leaving traders searching for a clear catalyst. Community discussions highlight concerns about cautious outlooks on the U.S. macroeconomic environment and potential headwinds from Caribbean capacity growth. Some traders are pointing to possible manipulation, while others are looking for a buying opportunity amid the uncertainty.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Tonix Pharmaceuticals Holding Corp

TNXP is trending as the community discusses the company's future prospects following the commercial launch of Tonmya, with some questioning its potential impact amidst concerns of dilution.  Bulls express optimism about the new drug and potential for a short squeeze, while bears cite concerns about the company's history and financial management. Discussions also include institutional ownership, possible buyback, and potential buyout.

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

Zoom Video Communications, Inc.

Zoom ($ZM) is trending as the community discusses its potential for AI-driven growth following recent earnings and analyst ratings updates, despite concerns about market competition and historical performance. Community talking points revolve around its cash reserves, innovation, and potential acquisitions. Broader discussions involve whether Zoom can move beyond its pandemic-era association and solidify its position in the UCaaS landscape.

Symbotic, Inc. is an automation technology company, which engages in a robotics and automation-based product movement technology platform. It focuses on developing, commercializing, and deploying innovative, end-to-end technology solutions for supply chain operations. It operates through the United States and Canada geographical segments. The company was founded by Richard B. Cohen on December 11, 2020 and is headquartered in Wilmington, MA.

Symbotic Inc - Ordinary Shares - Class A

Symbotic Inc 

Symbotic is trending following its Q4 earnings release, with community members weighing the positive revenue growth against concerns about valuation and customer concentration. Discussions also include the company's long-term potential in warehouse automation and the impact of recent shifts in risk factors, including retail dependency and supply chain vulnerabilities. Bullish sentiment remains, with some anticipating a continued rise and potential short squeeze.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending as investors discuss potential data integrity concerns from a recent trial and its implications for future FDA meetings. Community members are debating the validity and impact of the data, with some suggesting a possible buyout or partnership on the horizon. The stock's movement is also influenced by competitor activity and discussions around potential acquisition targets.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

GALT is trending as traders discuss trading halts on some platforms, potential manipulation, and the possible implications for shorts; the community speculates this could be related to upcoming news or a potential short squeeze. Chatter about brokerages restricting buying has fueled speculation, while others point to the strong science and data presented as a positive catalyst. Discussions about a potential buyout continue, with many closely watching for FDA feedback.

Fluence Energy, Inc. engages in energy storage products and services, and artificial intelligence-enabled digital applications for renewables and storage. The company was founded on June 21, 2021, and is headquartered in Arlington, VA.

Fluence Energy Inc - Ordinary Shares - Class A

Fluence Energy ($FLNC) is trending following Q4 earnings and fiscal year 2026 guidance, with the community highlighting record order intake and backlog growth, signaling strong expansion in the BESS (Battery Energy Storage Systems) market. Bullish sentiment is fueled by the company's outlook, with many believing revenue guidance will be surpassed. Discussions also involve potential benefits from domestic content strategies and increased demand driven by AI and data centers.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending due to positive sentiment around its role in AI infrastructure, particularly following Google's Gemini 3 model announcement and news of potential Saudi investment in AI chips. Community members are weighing AVGO's AI prospects against those of competitors like NVDA, with some highlighting Broadcom's custom chip advantage and attractive dividend yield, while others point to a potential overvaluation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company raised its full-year adjusted earnings guidance to at least $2 per share, up from its previous guidance of at least $1.75.</li><li>The company also said it conducted a quantitative impairment analysis in the third quarter to determine whether goodwill was impaired.</li><li>The analysis was completed in October, and the company recorded a non-cash goodwill impairment of $6.7 billion, it said. &nbsp;</li></ul>Centene Corporation (CNC) on Wednesday raised its full-year adjusted earnings (EPS) forecast after it posted an unexpected profit in the third quarter.Analysts, on average, were expecting the insurer to post a loss of $0.18 per share in the third quarter, according to data from Fiscal AI. However, the company reported adjusted EPS of $0.50, sending shares rallying 10% in the premarket session.The company subsequently raised its full-year adjusted earnings guidance to at least $2 per share, up from its previous guidance of at least $1.75.Medical cost ratio, or the percentage of premiums used on medical care, in the three months through the end of September was 92.7%, up from the 89.2% reported in the corresponding period of 2024. The company pinned the increase to higher medical costs in the Medicaid business, among other factors.&nbsp;The company also said that it performed a quantitative impairment analysis during the third quarter to determine whether goodwill was impaired after the implementation of President Trump's tax and budget bill, as well as a decline in the company’s stock price.The analysis was completed in October, and the company recorded a non-cash goodwill impairment of $6.7 billion, it said.&nbsp;Get updates to this developing story directly on Stocktwits.

In this photo illustration a Centene Corporation logo seen displayed on a smartphone with the stock market information of Centene Corporation in the background. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Centene Raises Full-Year Earnings Guidance After Posting Unexpected Profit In Q3

The company raised its full-year adjusted earnings guidance to at least $2 per share, up from its previous guidance of at least $1.75.

Equity

<ul class="summary-bullets"><li>UNH raised its full-year adjusted earnings guidance to at least $16.25 per share, up from its previous outlook of at least $16.&nbsp;</li><li>However, company executives warned on the company’s earnings call that the path to recovery in its Medicaid business will be challenging.</li><li>They noted that medical cost trends remain historically high but consistent with the company’s second-quarter guidance.&nbsp;</li></ul>UnitedHealth Group (UNH) on Tuesday raised its full-year adjusted earnings guidance to at least $16.25 per share, up from its previous outlook of at least $16, as it seeks to return to growth in 2026.“We remain focused on strengthening performance and positioning for durable and accelerating growth in 2026 and beyond, and our results this quarter reflect solid execution toward that goal,” said CEO Stephen Hemsley.“Simply put, we will end 2025 well-positioned for a return to solid growth in 2026, acceleration in 2027, and a clear focus on our long-standing mission and strategy,” the CEO noted during the company’s third quarter (Q3) earnings call, while adding that the company intends to share its 2026 full guidance in January with its fourth quarter (Q4) earnings.Hemsley took over the reins of the company in May after former CEO Andrew Witty stepped down. He is also the chairman of UNH’s board of directors.<h2 class="st-heading-2">Execs Flag Concerns On Medicaid Business Recovery</h2>However, company executives warned on the earnings call that the path to recovery for the company’s Medicaid business will be challenging. Medicaid is a joint federal and state program in the United States that provides low-cost or free health coverage to eligible low-income individuals.“States have not funded in line with actual cost trends, so funding levels are not sufficient to cover the health needs of state enrollees. While we're making steady progress in bridging this gap with states, the mismatch between rate adequacy and member acuity will likely extend through 2026," Hemsley said, according to an earnings call transcript provided by Fiscal AI. A company executive also noted that the elevated cost trends in the business were driven by specialty pharmacy, behavioral health, and home health services in the third quarter.<h2 class="st-heading-2">UnitedHealth’s Q3 Numbers</h2>For the third quarter, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.unitedhealthgroup.com/newsroom/2025/2025-10-28-uhg-reports-third-quarter-2025-results-and-raises-full-year-2025-earnings-outlook.html">reported</a> a 12% increase in consolidated revenue to $113.2 billion, above an analyst estimate of $113.06 billion, as cited by Fiscal AI.Adjusted earnings per share came in at $2.92, above an expected $2.81.Medical cost ratio, or the percentage of premiums used on medical care, was 89.9%, in line with the expectations put forth by the company in the second quarter (Q2). Company executives noted on the earnings call that medical cost trends remain historically high but consistent with its second quarter guidance, and the insurer expects that to continue throughout the remainder of 2025.The company’s revenue from its key Optum business segment, meanwhile, grew 8% year-over-year to $69.2 billion.Shares of the company traded 2% higher at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/UNH">UNH stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.A Stocktwits user expressed optimism for the stock yielding significant profits in the future.<stembedurl>https://stocktwits.com/_Texan_/message/634014037</stembedurl>Another user resonated the sentiment.<stembedurl>https://stocktwits.com/Smoothbrainape/message/634012667</stembedurl>UNH stock is down by 27% this year and by about 34% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-on-look-out-for-manufacturing-engineer-to-advance-new-roadster-sports-ev/cLGjVUAR3vE">Tesla On The Look-Out For Manufacturing Engineer To Advance Its New Roadster Sports EV</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the UnitedHealth Group logo is displayed on the screen of a smartphone. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

UnitedHealth Increases Full Year Earnings Forecast But Warns Of Tough Road Ahead For Medicaid Business

UNH raised its full-year adjusted earnings guidance to at least $16.25 per share, up from its previous outlook of at least $16. 

SoFi Technologies (SOFI) stock became the top trending ticker on Stocktwits on Friday morning and witnessed over a 60% increase in retail user message count in the last 24 hours after the company’s platform, Galileo Financial Technologies, announced it had joined the Amazon Web Services (AWS) partner network.The partnership is to expand access to Galileo Financial’s payment processing solutions. The company announced that businesses across various industries can now utilize Galileo’s platform on AWS to develop, deploy, and scale modern financial experiences.As an Amazon partner network member, Galileo joins a global network of 130,000 Partners from more than 200 countries working with AWS.“By joining the AWS Partner Network, we’re meeting businesses where they already are, making it faster and easier for them to access our financial technology and bring new financial products to their customers,” said Sandy Weil, Chief Revenue Officer at Galileo, SoFi’s Technology Platform.<a href="https://stocktwits.com/symbol/SOFI">Shares of SoFi Technologies</a> were down nearly 2% before the bell on Friday. Retail sentiment on the stock dipped to ‘bearish’ from ‘neutral’ territory compared to a day ago, with message volumes at ‘normal’ levels, according to data from Stocktwits.On Wednesday, Keefe Bruyette analyst Timothy Switzer raised the price target on SoFi Technologies to $18 from $14 and maintained an ‘Underperform’ rating, according to TheFly. The firm increased its estimates ahead of the company's third-quarter results on October 28 to reflect higher net interest income and momentum in the loan platform business.While "several positive potential catalysts" could bring support for the shares in the near term, SoFi's risk and reward "seems skewed negatively over the long term given the premium valuation," Switzer said.Shares of SoFi Technologies have jumped 73% this year and have gained over 161% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/american-express-stock-slips-ahead-of-q3-earnings/ch6sdiWR3Fx">American Express Stock Slips Ahead Of Q3 Earnings: Retail Sentiment Turns Bullish</a>

The SoFi Technologies, Inc. logo appears on a smartphone screen in this illustration photo in Reno, United States, on December 20, 2024.

SOFI Stock Is The Talk Of The Town Today, And There’s An Amazon Angle

Galileo Financial said that as an Amazon partner network member, it joins a global network of 130,000 partners from more than 200 countries working with AWS.

Pfizer (PFE) CEO Albert Bourla reportedly said on Wednesday that vaccines are harder to get approved while Health Secretary Robert F. Kennedy Jr. oversees the U.S. Food and Drug Administration.Kennedy Jr., a known vaccine skeptic, is currently attempting to overhaul vaccine policies in the U.S.“It’s not harder to get drug approvals right now. It’s harder to get vaccine approvals,” Bourla said at a CNBC event in Washington, as <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-10-15/pfizer-ceo-says-vaccine-approvals-are-harder-to-get-right-now">reported</a> by Bloomberg.The U.S. Food and Drug Administration under Kennedy Jr. in May said they would adopt a new COVID-19 vaccination regulatory framework, requiring new clinical trials to approve annual vaccine booster shots in healthy individuals under 65.The agency said that it will approve vaccines for high-risk persons such as adults 65 and older and individuals above the age of six months with risk factors putting them at high risk for severe infections, but demand “robust, gold-standard data” for healthy people under 65.The agency approved an updated version of a COVID-19 vaccine made by Pfizer and BioNTech in August, but only for use in senior adults as well as in younger individuals who are at risk of severe outcomes from the infection.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PFE">PFE stock</a> rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:589/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_15_at_1_00_03_PM_png_d8656d4532.webp" alt="PFE's Sentiment Meter and Message Volume as of 1:00 p.m. ET on Oct. 15, 2025 | Source: Stocktwits" width="589" height="61"><figcaption>PFE's Sentiment Meter and Message Volume as of 1:00 p.m. ET on Oct. 15, 2025 | Source: Stocktwits</figcaption></figure>On Tuesday, Bourla <a href="https://stocktwits.com/news-articles/markets/equity/pfizer-ceo-urges-us-china-collaboration-in-pharma-stock-drops-for-7th-day-as-traders-dividend-payout/ch6nSZkR3ZK">spoke</a> at the National Committee on U.S.-China Relations Gala in New York and said that the U.S. pharmaceutical industry should work more collaboratively with China, whose “dramatic speed, cost and scale” have reshaped global drug development.Late last month, Pfizer also <a href="https://stocktwits.com/news-articles/markets/equity/trump-announces-pfizer-drug-pricing-deal-company-to-invest-70-billion-in-us-manufacturing/chDDgU5R39O">inked</a> a deal with the Trump administration, which features steep price cuts on several drugs and a $70 billion U.S. investment in return for a three-year exemption from the President’s pharmaceutical tariffs.PFE stock is down by 9% this year and by about 17% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sana-biotech-stock-jumps-after-eric-jackson-calls-it-next-100-bagger-platform/ch6FG0MR3Nu">Sana Biotech Stock Jumps A Whopping 35% After Eric Jackson Calls It ‘Next 100-Bagger Platform’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Pfizer’s logo is on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Pfizer CEO Reportedly Says Vaccine Approvals Getting Harder

According to a report from Bloomberg, Bourla said that it's harder to get vaccine approvals and not drug approvals. 

UnitedHealth Group’s (UNH) shareholder Accountability Board has reportedly filed a proposal seeking an independent chairman of the board, separate from the CEO.Bloomberg <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-10-03/unitedhealth-shareholder-wants-chairman-and-ceo-roles-separated">reported</a> on Friday that the nonprofit advocacy group’s proposal, if approved by shareholders, would ask the board to amend the company’s bylaws to codify an independent board chair. Currently, Stephen Hemsley serves as both CEO and chair of the board.“We were very disturbed to see recently that at such a trying time for UnitedHealth, the company chose to go backward and combine the CEO and chair roles,” Accountability Board President Matt Prescott said, as reported by Bloomberg. Prescott also called for a stronger leadership structure at the insurer while declining to disclose the size of the group’s stake in UNH, the report said. However, he noted that the stake meets the minimum requirement to file a shareholder proposal.The report noted that it is unclear whether the Accountability Board’s resolution will proceed to a shareholder vote.Shares of UNH traded 3% higher at the time of writing. On Stocktwits, retail sentiment regarding <a href="https://stocktwits.com/symbol/UNH">UNH stock</a> remained within the ‘bearish’ territory, while message volume remained at ‘low’ levels.Hemsley has been chairman of the company’s Board of Directors since 2017. Before that, he also served as CEO. He was reappointed as CEO in May when Witty <a href="https://stocktwits.com/news-articles/markets/equity/unitedhealth-suspends-2025-guidance-ceo-andrew-witty-resigns/chi8S4qRbZQ">stepped down</a>, citing personal reasons, but while retaining his chair position. This is contradictory to UnitedHealth’s principle of governance, which also calls for separate roles, Bloomberg noted.The insurer issued <a href="https://stocktwits.com/news-articles/markets/equity/united-health-price-target-lowered-by-bernstein-after-soft-guidance-but-retail-hopes-for-long-term-recovery/chrXElQRdRK">fresh guidance</a> of full-year revenue of $445.5 billion to $448.0 billion and adjusted earnings of at least $16.00 per share in July after suspending its previous outlook in May, citing higher medical costs. The company had previously forecast adjusted profit of $29.50 to $30.00 per share, nearly double its latest forecast. The company also <a href="https://stocktwits.com/news-articles/markets/equity/united-health-s-cfo-shake-up-doesn-t-deter-retail-bulls-traders-call-stock-a-2018-level-opportunity/chr3k1VRdGi">appointed</a> Wayne S. DeVeydt as CFO in July, replacing John F.Rex.UNH stock is down 28% this year and approximately 39% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-gets-price-target-hike-from-jpmorgan-after-q3-deliveries-beat-estimates/chCumk4R3QJ">Tesla Gets A Price Target Hike From JPMorgan After Q3 Deliveries Beat Estimates</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of UnitedHealth Group Incorporated. (Photo illustration by Cheng Xin/Getty Images)

UnitedHealth Shareholder Proposes Distinct Chairman And Chief Executive Roles: Report

Stephen Hemsley currently serves as both CEO and Chairman of the Board.

Rivian Automotive, Inc. (RIVN) on Thursday said that it delivered 13,201 vehicles in the three months through the end of September, up from the 10,018 deliveries reported in the corresponding quarter of 2024.The company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251002676995/en/Rivian-Releases-Q3-2025-Production-and-Delivery-Figures-and-Sets-Date-for-Third-Quarter-2025-Financial-Results">slashed</a> its full-year delivery guidance to 41,500 to 43,500 vehicles from its previous forecast of between 40,000 and 46,000 cars, as EV demand is expected to dwindle following the expiry of the federal tax credit on the purchase of EVs on Sept. 30. Shares of the company fell 7% on Thursday morning at the time of writing.On Stocktwits, the retail sentiment around <a href="https://stocktwits.com/symbol/RIVN">RIVN stock</a> fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume fell from ‘normal’ to ‘low’ levels.The company also stated on Thursday that it produced 10,720 vehicles at its manufacturing facility in Normal, Illinois, during the quarter, down from the 13,157 manufactured in the corresponding period of 2024. The Normal facility is now Rivian’s only functioning manufacturing facility. Last month, the company broke ground on its Georgia facility, which could eventually produce 400,000 vehicles per year. Production at the facility is slated to start in 2028.Rivian is now ramping up for the launch of the R2 SUV in 2026. The midsize version is expected to launch in the first half of 2026 and is projected to have a price tag of $45,000. Rivian plans to manufacture validation builds of the vehicle later this year at its Illinois facility, which has the capacity to produce up to 215,000 vehicles annually. The company said the Georgia plant will provide additional capacity for the program.Currently, the company’s lineup in the U.S. comprises its R1T truck, R1S SUV, and electric delivery vans, with Amazon.com being the primary buyer. &nbsp;RIVN stock is up by 3% this year and by 28% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/anavex-life-sciences-stock-rallies-pre-market-after-investigational-drug-for-schizophrenia-meets-primary-endpoint-in-trial/chCrOwoR3Or">Anavex Life Sciences Stock Just Shot Up 7% Today – Here’s An Important Update</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.Editor's Note: The story has been updated to reflect the accurate delivery figure in the third quarter of 2024.

A Rivian charges outside of Blink Charging's new flagship manufacturing facility in Bowie, Md., on Monday March 11, 2024. (Tom Williams/CQ-Roll Call, Inc via Getty Images)

Rivian Slashes Full-Year Delivery Guidance Amid Uncertainty Related To Federal EV Tax Credit Expiry

The company slashed its delivery guidance to 41,500 to 43,500 vehicles for the full year. 

General Motors (GM) on Wednesday said that it delivered 710,347 vehicles in the U.S. in the third quarter (Q3), marking a growth of 7.7% year-over-year.Electric vehicle <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investor.gm.com/static-files/501fc28d-057f-413a-a4cc-0a8a7eaa8257">sales</a> in the quarter hit a fresh record of 66,501 units, marking a growth of 107%, as customers rushed to make their EV purchase before the expiry of the federal tax credit of $7,500 on September 30. The Chevrolet Equinox EV was the company’s best-selling EV in the quarter with 25,085 units delivered. Luxury segment EVs from GM’s Cadillac brand, including the Lyriq, Optiq, and Vistiq, also recorded significant delivery numbers despite higher price points.Chevrolet was the company’s best-selling brand in the quarter, with deliveries rising 8.3% to 710,347 units in the three months through the end of September. While the company’s Cadillac and GMC brands also recorded delivery growth in the quarter, Buick deliveries dropped a steep 14%. GMC is on pace for its best year ever, the company noted. Cadillac, meanwhile, recorded its best third quarter since 2013.Certain models across brands, such as the GMC Terrain, Chevrolet Equinox, Chevrolet Traverse, and Buick Envista, had their best-ever third-quarter sales, the company added. The firm also noted that its fleet business, called GM Evolve, reported a 20% increase in sales in the third quarter.<a href="https://stocktwits.com/symbol/GM">GM shares</a> rose 1% at the time of writing. On Stocktwits, retail sentiment around GM stock fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.GM stock is up by 15% this year and by 37% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/stellantis-expands-partnership-with-mistral-ai-amid-tough-ai-push/chCYBIDR3aU">Stellantis Expands Partnership With Mistral AI Amid Tough AI Push</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of General Motors is seen on a smartphone screen with a steering wheel in the background. (Photo Illustration by Serene Lee/SOPA Images/LightRocket via Getty Images)

General Motors Reports 7.7% Growth In Q3 Auto Sales In US

Electric vehicle sales in the quarter hit a fresh record of 66,501 units as customers rushed to make their EV purchase before the expiry of the federal tax credit of $7,500 on September 30.

Acadia Pharmaceuticals Inc. (ACAD) announced on Tuesday that its late-stage intranasal Carbetocin trial in Prader-Willi syndrome (PWS) patients did not achieve a statistically significant improvement in hyperphagia.The <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-announces-phase-3-compass-pws-trial">study</a> enrolled 175 children and adults aged five to 30 years with PWS, a rare genetic disorder characterized by an insatiable hunger or hyperphagia and a constant need for food, leading to obesity. However, intranasal Carbetocin did not demonstrate a statistically significant improvement over placebo to week 12 on the Hyperphagia Questionnaire for Clinical Trials, the company said.The firm noted that the safety and tolerability of intranasal Carbetocin were consistent with those observed in previous clinical trials, with a low rate of adverse events.Shares of the company tumbled 11% in the pre-market session. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ACAD">ACAD stock</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.Acadia’s Head of Research and Development, Elizabeth HZ Thompson, said that the company is “disappointed” by these findings. “We are committed to sharing a summary of the data in the future to ensure learning for the PWS community; however, given these results, we do not intend to investigate intranasal carbetocin any further,” Thompson added.CEO Catherine Owen Adams highlighted that the firm’s approved products are projected to generate over $1 billion in net sales in 2025 despite the disappointment with the trial. The company’s drugs for the treatment of Rett syndrome and for treating hallucinations and delusions associated with Parkinson’s disease psychosis are approved by the U.S. Food and Drug Administration.“Looking ahead, we anticipate seven Phase 2 or 3 study starts through 2026 and four data readouts by the end of 2027,” the CEO added.ACAD stock is up 29% this year and approximately 49% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-mp-materials-stock-rising-today/chD1R9FR330">Why Is MP Materials Stock Rising Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Acadia Pharmaceuticals company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Acadia Pharmaceuticals’ Investigational Drug For Rare Genetic Disorder Fails In Late-Stage Study 

The company noted that the safety and tolerability of intranasal Carbetocin were consistent with those observed in previous clinical trials.

Emergent BioSolutions Inc. (EBS) on Friday said that it has secured new purchase orders from an international government partner for a multiproduct supply agreement.The agreement is valued at $29 million, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-secures-29-million-mcm-product-orders">said</a>. The order encompasses several product offerings within Emergent’s medical countermeasures business, including countermeasures for threats posed by Smallpox, Anthrax, and Botulism. The company said that this is the second procurement made by the same government this year.Shares of the company jumped 3% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/EBS">EBS stock</a> rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:575/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_19_at_11_37_08_AM_png_46c276596d.webp" alt="EBS's Sentiment Meter and Message Volume as of 11:37 a.m. ET on Sept. 19, 2025 | Source: Stocktwits" width="575" height="61"><figcaption>EBS's Sentiment Meter and Message Volume as of 11:37 a.m. ET on Sept. 19, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the stock is “significantly undervalued,” while indicating that they see more than 100% upside.<stembedurl>https://stocktwits.com/NRG8/message/629302236</stembedurl>Another user expects the stock to hit $10 next week.<stembedurl>https://stocktwits.com/shoagh12/message/629291934</stembedurl>Emergent said it will receive about $26 million in 2025 under the agreement. This is in addition to more than $100 million in sales already generated for the company’s MCM portfolio outside the U.S. so far this year, it said.“Together with demand from the U.S. government, these international procurements reinforce the potential for our growth trajectory as part of Emergent’s multi-year transformation plan and highlights the strength of Emergent’s global footprint,” CEO Joe Papa said. The CEO also added that the company continues to see countries elevating their investment in defense preparedness.Emergent delivers solutions for health threats like Smallpox, Mpox, Botulism, Ebola, Anthrax, and Opioid overdose emergencies.Earlier this week, the company also announced that it has received a $17 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA) to supply Tembexa oral suspension. At the start of the month, the company also announced that a contract modification had been executed for $56 million to supply ACAM2000, a live vaccinia virus vaccine approved by the FDA for use in preventing Smallpox and Mpox in individuals at high risk of infection, to the U.S. government.EBS stock is down 14% this year but up approximately 17% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/paramount-skydance-likely-preparing-22to24-per-share-bid-for-warner-bros-discovery/chD34ulR3Ta">Paramount Skydance Likely Preparing $22 To $24 Per Share Bid For Warner Bros. Discovery: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the Emergent BioSolutions logo of an US biopharmaceutical company is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Emergent BioSolutions Stock Rises After Receiving Fresh International Purchase Orders: Retail Says Stock Is ‘Significantly Undervalued’

The order encompasses multiple product offerings within Emergent’s medical countermeasures business, including countermeasures for threats posed by Smallpox, Anthrax, and Botulism.

RH Stock Sees Slew Of Downgrades, Price Target Cuts From Wall Street As Trump Tariffs Bite

Telsey Advisory Group stated that if an additional sector tariff on furniture is imposed, RH has the highest exposure within the home furnishings coverage group due to a high percentage of sales from furniture and limited sourcing in the U.S.

American Century ETF Trust - Avantis Responsible U.S. Equity ETF

Buying

Holding

Selling or trimming

Watching from the sidelines

What are you doing with Alphabet ($GOOGL) stock as it hits fresh all-time highs?

AVSU
American Century ETF Trust - Avantis Responsible U.S. Equity ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest AVSU News

AVSUAmerican Century ETF Trust - Avantis Responsible U.S. Equity ETF